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Abstract
Introduction
Multimorbidity and polypharmacy are current challenges when caring for the older population.
Both have led to an increase of potentially inappropriate medication (PIM), illustrating the need
to assess patients’ attitudes towards deprescribing. We aimed to assess the prevalence of PIM
use and whether this was associated with patient factors and willingness to deprescribe.
Method
We analysed data from the LESS Study, a cross-sectional study on self-reported medication
and on barriers and enablers towards the willingness to deprescribe (rPATD questionnaire).
The survey was conducted among multimorbid (�3 chronic conditions) participants�70
years with polypharmacy (�5 long-term medications). A subset of the Beers 2019 criteria
was applied for the assessment of medication appropriateness.
Results
Data from 300 patients were analysed. The mean age was 79.1 years (SD 5.7). 53% had at
least one PIM (men: 47.8%%, women: 60.4%%; p = 0.007). A higher number of medications
was associated with PIM use (p = 0.002). We found high willingness to deprescribe in both
participants with and without PIM. Willingness to deprescribe was not associated with PIM
use (p = 0.25), nor number of PIMs (p = 0.81).
Conclusion
The willingness of older adults with polypharmacy towards deprescribing was not associ-
ated with PIM use in this study. These results suggest that patients may not be aware if they
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are taking PIMs. This implies the need for raising patients’ awareness about PIMs through
education, especially in females, in order to implement deprescribing in daily practice.
Background
An ageing population with multimorbidity (�3 chronic conditions) and polypharmacy (�5
long-term medications) poses a worldwide challenge to healthcare organisations, particularly
in primary healthcare. As the prevalence of polypharmacy has increased due to high multimor-
bidity in especially the older population, potentially inappropriate medication (PIM) use has
increased as well [1–3]. The single most important risk factor for PIM use is the number of
prescribed medications [4]. Medications are considered ‘potentially inappropriate’ when its
potential risk outweighs its clinical benefit in an individual [5]. Previous studies have reported
a prevalence of PIMs between 40–80% [6–9]. Due to associated negative health consequences
(e.g. reduced adherence and quality of life and increased risk of adverse drug reactions and
hospitalizations), PIMs are an unnecessary burden to the older population [10–12].
Appropriate prescribing in the older population is challenging. First, older individuals have
an increased risk of medication-related harm due to an age-related change in pharmacokinet-
ics and -dynamics, a lower physiological reserve and drug-drug or drug-disease interactions
[13–15]. Additionally, they are more susceptible to PIMs due to a lack of evidence regarding
the benefits and harms of medications in multimorbid older adults and the frequently
observed “prescribing cascade” where new medication is prescribed to treat a side effect of
another medication [16]. Lastly, the application of single disease evidence-based guidelines to
an individual with multimorbidity results in complex polypharmacy as they do not take into
account potential drug- and disease-drug interactions [17,18].
The high prevalence and negative impact of PIMs, as well as the need to individualise ther-
apy illustrates the importance of deprescribing in older individuals. Deprescribing is the pro-
cess of withdrawal or dose reduction of inappropriate medications, supervised by a healthcare
professional. This is endorsed by more recent guidelines, such as the NICE guidelines on mul-
timorbidity and medication optimisation, that were developed to reduce polypharmacy and
PIMs by recommending approaches on how to best manage and optimise pharmaceutical
treatment in complex older adults [19,20].
Currently, deprescribing tools that assist physicians in detecting PIMs are increasingly
being applied in daily practice. An example is the AGS Beers criteria, which is a globally used
tool that lists PIMs that should be avoided in most older adults due to increased risk of harm
or low/no benefit. Deprescribing can have a considerable positive impact on the health status
and treatment burden of the older multimorbid population [21]. It may reduce adverse drug
reactions, improve patients’ quality of life and promote medication adherence [22–24]. Under-
standing patients’ attitudes towards their medications and deprescribing can inform patient-
centered care which is a key part of all clinical care [18].
Patients beliefs and attitudes towards deprescribing have increasingly been investigated
[1,25–30], but whether these are correlated with appropriateness of their medications has not
yet been determined. So far, quantitative research has mostly reported patients’ and clinicians’
attitudes towards deprescribing and investigated its relationship with patient-related factors
(such as age). To date, the only medication-related factor that the revised Patients’ Attitudes
Towards Deprescribing questionnaire (rPATD) has been related with is the number of pre-
scribed medications, with studies finding inconsistent results. It is not yet known how attitudes
towards deprescribing may be related to the suitability of that individual for deprescribing (i.e.
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whether they are taking a PIM). We hypothesized that patients who use PIMs experience more
side effects than patients who do not use any PIMs, which in turn might affect their willingness
to deprescribe.
In this study, we investigated whether there is an association of PIM use and willingness to
deprescribe in older individuals and which factors influence patients’ attitudes towards deprescrib-
ing. Second, we were interested to see how prevalent PIM was in a population of older patients
with polypharmacy and which types of PIMs were most commonly used in men and women.
Methods
Design
The current study was nested in the LESS Study [31], which is a cross-sectional anonymous
survey-study that evaluates the overall willingness to deprescribe and the barriers and enablers
towards the willingness to deprescribe in older Swiss individuals with multimorbidity and
polypharmacy. This manuscript reports the results of patients’ attitudes towards deprescribing
related to PIMs.
Study population
Sixty-four general practitioners (GPs) from the German-speaking part of Switzerland recruited
primary care patients for involvement in this study. All of them were located in different GP
offices. Eligible patients were�70 years old with multimorbidity and polypharmacy. Multi-
morbidity was defined as the presence of�3 chronic diseases, with chronic diseases being
present for at least six consecutive months [32]. Polypharmacy was defined as the concurrent
use of�5 long-term medications [33,34]. GPs were instructed to consecutively screen eligible
patients and recruit 5 participants, reporting the number of patients screened, to reduce the
risk of selection bias. The questionnaire was completed by a total of 306 patients, 6 of whom
were excluded based on missing information about prescribed medication. Patients anony-
mously filled in the survey and handed it back to the practice nurse to limit the chance of social
desirability bias.
Questionnaire
For this study, we used data from 300 questionnaires on demographic status like age, gender,
living situation, help with medication intake, involvement in medication self-management
and education level. As for willingness to deprescribe, we used data from the revised Patients’
Attitudes Towards Deprescribing questionnaire (rPATD). This is a validated and reliable tool
that has been applied in multiple studies [1,35–38]. It contains 22 questions on a 5-point Likert
scale, ranging from “strongly agree” to “strongly disagree” which relate to beliefs and attitudes
about their medications and deprescribing [37]. The rPATD was translated into German as
previously described [31].
Medication appropriateness
In the present study, we used the self-reported list of prescribed medications and medication
dosages for the assessment of PIMs. Self-reported medication is proven accurate and valid for
long-term medication in the general population [39,40] and was chosen in this case to specifi-
cally focus on which medications patients report they take. The self-reported medication list
was checked for inconsistencies (e.g. spelling errors) before analysis of PIMs was performed.
In case of uncertainty regarding self-reported medication (e.g. due to poor or unreadable
handwriting), in consultation with a GP researcher, the best applicable option was chosen
PLOS ONE Potentially inappropriate medication and attitudes of older adults towards deprescribing
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[41]. Next, each medication was coded according to the WHO ATC-coding system. For the
assessment of medication appropriateness, a selection of the AGS Beers 2019 criteria was used
[42]. The AGS Beers list is the most commonly used tool for assessment of PIMs worldwide
[43]. Since data on medical conditions was limited in this study, we used only the criteria that
were applicable without clinical information (52 of 97 criteria). A list of the included criteria is
added in S1 Appendix. Criteria were excluded based on weak strength of evidence as defined
in the AGS Beers list (n = 8) or lack of information (n = 37). Application of a subset of the
Beers 2019 criteria is in line with previous studies that used subsets of the Beers criteria for
assessing medication appropriateness [29,44–46].
Willingness to deprescribe
Our main outcome was the willingness to deprescribe in relation to medication appropriate-
ness. We therefore analysed data from the rPATD where patients were asked if they are satis-
fied with their current medications and if they are willing to deprescribe if their doctor said it
was possible, along with 20 other questions grouped into four factors: involvement, burden,
appropriateness and concerns about stopping, as described elsewhere [1].
Ethics
Ethical approval for this study was obtained from the Ethics Committee of the Canton of Bern,
Switzerland (Ref. 2017–02188). All patients provided written informed consent before partici-
pating in the study.
Statistical analysis
Before the analysis, consistency checks were performed on the complete data set including the
AGS Beers criteria and uncertainties were resolved by consensus of two researchers. Descrip-
tive results were presented in frequencies, proportions, means and standard deviations (SD),
and 95% confidence intervals (CI) were appropriate. Hypothesis testing for categorical vari-
ables was done using Chi-squared tests and simple linear regression for continuous variables
when normally distributed. Patients with at least one PIM in their medication list where
grouped to ‘PIM yes’, all others to ‘PIM no’ (exposure).
The individual scores (n = 22) of the rPATD showed a non-normal distribution. For the
multivariate model we therefore dichotomized each of the 5-point Likert questions as well as
factor scores according to the median as done previously [1]. Individual scores equal to or
higher than the median were placed in the “high score” group, whereas scores below the
median were placed in the “low score” group. In a multivariate model with different compo-
nents of the rPATD as the outcome (satisfaction, willingness to stop, involvement, burden,
appropriateness, concerns about stopping) [1], we calculated odds ratios (OR) and adjusted
for age, gender and number of medications. To account for possible clustering of answers
from patients from the same GP, we chose a mixed-effects model with the individual GP as
random-effects. In a sensitivity analysis, we repeated the same models but with number of
PIMs as the exposure instead of PIM yes vs. no. Significance level was set at<0.05. Data analy-
ses were performed using STATA version 15.2 (Stata Corp, College Station, TX, USA).
Results
For the overall analysis of polypharmacy levels and PIM, 300 participants were included, col-
lectively taking approximately 2700 medications. Seventy-eight percent of all participants used
5–9 regular medications, with the remaining 22% using�10 medications (excessive
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polypharmacy). Participants received on average 8 medications (SD 2.7). More than half of
our sample (54%) received at least 1 PIM. The majority received 1 PIM (31.3%), 12.7%
received 2 PIMs and 9.7% received�3 PIMs up to 7 PIMs. Gender distribution was approxi-
mately even, and participants had a mean age of 79.1 years (SD 5.7). The baseline characteris-
tics of participants in each group (no PIM, 1 PIM and>1 PIM) are presented in Table 1. Age,
living situation, medication self-management and education level did not significantly differ
between participants receiving appropriate medication or PIM. We did, however, find an asso-
ciation of females having more PIM (p = 0.007) than men. Additionally, an association was
found between a higher number of prescribed medications and PIMs (p = 0.002). Thus,
patients receiving 10 or more medications (i.e. excessive polypharmacy) showed a significantly
higher risk of taking PIMs (Table 1).
Fig 1 illustrates the proportion of participants who agreed to the individual questions about
satisfaction with treatment and willingness to deprescribe and the proportion of participants
with high factor scores stratified by PIM. The majority of participants were satisfied with their
current medications (97.1% without PIM vs. 96.9% with PIM; p = 0.90) and were willing to
have one or more of their medications deprescribed (74.3% without PIM, 79.9% with PIM;
p = 0.25). From the four factor scores, we found more participants with PIM had high burden
scores (61% vs. 49%; p = 0.029) and less had high concerns about stopping scores (53% vs.
65%; p = 0.034). The table in S2 Appendix provides more detail about the rPATD factors as
shown in Fig 1. However, in the adjusted model the only association remaining was concerns
about stopping which was significantly lower in patients with PIM compared to those without
PIM (OR 0.55; 95%CI 0.33–0.92; p = 0.023). Moreover, this association disappeared in the sen-
sitivity analysis where number of PIMs was the exposure instead of PIM yes vs. no (OR 0.86;
95%CI 0.69–1.09; p = 0.21).
The level of agreement to all individual rPATD questions for participants with PIM as com-
pared to participants without PIM is presented in Table 2. There was a statistically significant
difference in the proportion of participants who agreed with the question, “If my doctor rec-
ommended stopping a medicine I would feel that he/she was giving up on me” in participants
taking�1 PIM compared to those without PIM (OR 0.49; 95%CI 0.29–0.82); p = 0.006). In the
sensitivity analysis with number of PIMs as the exposure, the association became weaker (OR
0.80; 95%CI 0.62–1.02; p = 0.07).
Table 1. Baseline characteristics of participants stratified by medication appropriateness.
Baseline characteristics Overall
n = 300
No PIM
n = 139 (46%)
1 PIM
n = 94 (31%)
>1 PIM
n = 67 (22%)
p-valuea
Female, n % 139 (46) 55 (40) 42 (45) 42 (63) 0.007
Age, mean (SD) 79.1 (5.7) 79.0 (5.5) 78.9 (6.0) 79.5 (6.0) 0.61
Living alone, n % 100 (34) 49 (36) 27 (29) 24 (36) 0.48
Self-management of medication, n % 257 (86) 120 (87) 83 (88) 54 (82) 0.48
Education level, n % 0.33
Basic education 86 (29) 34 (24) 28 (30) 24 (36)
Apprenticeship 146 (49) 68 (49) 49 (52) 29 (43)
Higher education 68 (23) 37 (27) 17 (18) 14 (21)
Number of medicines, mean (SD) 8.0 (2.7) 7.4 (2.3) 7.8 (2.4) 9.4 (3.5) <0.001
5–9 medicines 233 (78) 117 (84) 74 (79) 42 (63)
�10 medicines 67 (22) 22 (16) 20 (21) 25 (37) 0.002
Abbreviations: SD, standard deviation; PIM, potentially inappropriate medication.
ap-value is significant at <0.05.
https://doi.org/10.1371/journal.pone.0240463.t001
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Fig 2 lists types of PIMs according to the 2019 AGS Beers criteria and their frequency by
gender. We found proton pump inhibitors and benzodiazepines to be among the most fre-
quent PIMs in our sample. Additionally, we found that certain PIMs differed by gender. Ben-
zodiazepines (p<0.001), nonbenzodiazepines (p = 0.003), combinations of�3 CNS-active
drugs (p = 0.001) and opioids in combination with benzodiazepines (p = 0.004) were signifi-
cantly more frequent in females compared to males. Other drugs differed by gender as well
including (peripheral alpha-1 blockers and estrogens).
Discussion
Summary
In this study, we found PIM to be prevalent (54%) in a consecutive sample of older patients
with multimorbidity and polypharmacy in a primary care setting. PIM use was found to be
higher in patients with more prescribed medications compared to less. Interestingly, females
were more frequently prescribed a PIM, mostly benzodiazepines or other CNS-active drugs,
than males. We observed no difference in patients’ attitudes and willingness to deprescribe in
patients with or without PIM. Our findings suggest that willingness to deprescribe is equally
high in patients with and without PIM. There was also no difference in the adjusted analysis in
burden, appropriateness or involvement factor scores, but participants taking PIM had lower
concerns about stopping. This may therefore indicate that older adults with polypharmacy are
not aware of whether they are taking potentially inappropriate medications or not. Therefore,
efforts to increase awareness of the concept of PIM may be beneficial to shared-decision mak-
ing about deprescribing in regular practice. Our study has also highlighted some areas that
could be targeted, such as long term use of benzodiazepines in females.
Fig 1. Proportion of participants who agreed to the individual questions about satisfaction with treatment and
willingness to deprescribe and the proportion of participants with high factor scores stratified by PIM.
Involvement, burden, appropriateness and concerns about stopping are factor scores from the rPATD questionnaire
[25]. Each of the four factors consisted of 5 questions of which the possible score ranged from 1–5. We grouped the
answers of each patient to either ‘yes’ (if the factor score was higher than the median) or ‘no’ (if the factor score was
lower than the median). We then calculate the proportion of patients answering “yes”. Abbreviations: PIM, potentially
inappropriate medication; rPATD, revised patients’ attitudes towards deprescribing. p-value is significant at<0.05.
https://doi.org/10.1371/journal.pone.0240463.g001
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Table 2. Level of agreement to deprescribing in patients with PIM compared to patients without PIM.
rPATD questionsa Odds ratiob for PIM
vs no PIM
95% CI p-
valuec
“Overall, I am satisfied with my current medicines” 1.06 0.25–
4.45
0.93
“I like to be involved in making decisions about my medicines with my
doctors”
1.22 0.68–
2.21
0.51
“I have a good understanding of the reasons I was prescribed each of my
medicines”
1.34 0.79–
2.29
0.28
“I like to know as much as possible about my medicines” 1.01 0.61–
1.65
0.98
“I always ask my doctor, pharmacist or other health care professional if
there is something I don’t understand about my medicine”
1.13 0.68–
1.89
0.63
“I know exactly what medicines I am currently taking, and/or I keep an
up to date list of my medicines”
1.10 0.55–
2.18
0.79
“If my doctor said it was possible I would be willing to stop one or more
of my regular medicines”
1.60 0.87–
2.94
0.13
“I feel that I am taking a large number of medicines” 1.37 0.81–
2.30
0.24
“Taking my medicines every day is very inconvenient” 0.89 0.51–
1.54
0.67
“I spend a lot of money on my medicines” 0.91 0.54–
1.53
0.72
“Sometimes I think I take too many medicines” 1.21 0.73–
2.01
0.46
“I feel that my medicines are a burden to me” 0.86 0.53–
1.41
0.56
“I would like to try stopping one of my medicines to see how I feel
without it”
0.85 0.51–
1.40
0.51
“I would like my doctor to reduce the dose of one or more of my
medicines”
1.18 0.72–
1.92
0.52
“I feel that I may be taking one or more medicines that I no longer need” 1.47 0.91–
2.38
0.12
“I believe one or more of my medicines may be currently giving me side
effects”
1.14 0.68–
1.92
0.61
“I think one or more of my medicines may not be working 0.94 0.13–
7.08
0.95
“I have had a bad experience when stopping a medicine before” 0.60 0.35–
1.03
0.06
“I would be reluctant to stop a medicine that I had been taking for a long
time”
0.71 0.43–
1.15
0.16
“If one of my medicines was stopped I would be worried about missing
out on future benefits”
0.77 0.48–
1.25
0.30
“I get stressed whenever changes are made to my medicines” 0.82 0.50–
1.36
0.45
“If my doctor recommended stopping a medicine I would feel that he/
she was giving up on me”
0.49 0.29–
0.82
0.006
Abbreviations: rPATD, revised patients’ attitudes towards deprescribing; PIM, potentially inappropriate medication;
CI, confidence interval.
a from [25].
b Odds ratio is adjusted for age, sex, number of medicines and general practitioners.
c p-value is significat at <0.05.
https://doi.org/10.1371/journal.pone.0240463.t002
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Comparison with existing literature
The proportion of participants receiving at least one PIM matches previous studies from sev-
eral countries worldwide, which generally report prevalence’s between 40 and 80% [6–9,47].
We demonstrated that patients receiving 10 or more medications show a significantly higher
risk of PIMs. This confirms findings from previous studies that the number of medications is
the most important risk factor for PIMs [4,8,48]. Furthermore, we detected a correlation
between gender and prevalence of PIMs. It has been previously reported that females receive
a higher number of PIMs on average than males [7,47–50]. It has been suggested that this
might be due to females being at a higher risk for developing multiple chronic conditions
compared to males. This would imply that they are more susceptible to drug-drug and drug-
disease interactions, which challenges appropriate prescribing [47]. Yet, the actual reason for
this gender-difference is unknown. Similar to previous studies internationally [29,51], proton-
pump inhibitors and benzodiazepines were the most common PIMs identified in our study
population.
Interestingly, we found that patients’ reported willingness to deprescribe is not related to
PIM use according to the 2019 AGS Beers criteria. As investigated in a recent study on PIM
and deprescribing interventions that explored factors associated with deprescribing refusal,
likewise, PIM use was not associated with acceptance or refusal of deprescribing [29]. Previous
qualitative studies on deprescribing, have reported that patients generally lack knowledge of
the potential harms of medications and rely on the GP as a central and prominent figure in
decision-making [52,53]. These findings suggest that older adults are not aware of whether
their medications are appropriate or not. Reported willingness to deprescribe was equally high
in our participants with and without PIM. Furthermore, very few of the individual factors had
evidence to support a relationship with the use of PIMs, which stems from the fact that the
study might not have been sufficiently powered to detect such differences. The factors ‘burden’
and ‘concerns about stopping’ were associated in the unadjusted analyses, but the burden
Fig 2. Potentially inappropriate medication stratified by gender. Abbreviations: NSAIDs, nonsteroidal anti-
inflammatory drugs; CNS, central nervous system. p-value is significant at<0.05.
https://doi.org/10.1371/journal.pone.0240463.g002
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association was lost in the adjusted analyses (likely because of the confounding nature of PIMs
being associated with number of medications). Therefore, it is still unclear if and how use of
inappropriate medications influences attitudes and beliefs or vice versa. The overall high will-
ingness of older adults with polypharmacy to deprescribe is promising for further implementa-
tion of deprescribing in primary healthcare and is in line with prior studies investigating
patients’ attitudes towards deprescribing [1,25–30].
Limitations and strengths
We acknowledge several limitations in our study. First, we gathered information on prescribed
medications through self-reported medication lists, which might have affected the complete-
ness of the medication lists. The accuracy of self-reported medication data can vary with medi-
cation type and duration; with self-reporting generally being more accurate for long-term
medications [39,40]. Specifically, certain medication categories (e.g. psychoanaleptics and
analgesics) were previously found to be less reliably self-reported [40]. Therefore, by using
self-reported medication lists in this study, our results may be an underestimation of the use of
PIMs. Second, the prevalence of PIMs in our sample might be underestimated due to the lim-
ited generalizability of the Beers criteria, published by the American Geriatrics Society, as they
are based on medications commonly prescribed in the United States. Additionally, the Beers
criteria capture ‘potentially’ inappropriate medications and so the assessment of appropriate-
ness is not individualised. Third, the recruitment of study participants by GPs could have
introduced selection bias. However, since consecutive sampling was used for participant inclu-
sion–as it was not possible to recruit a random sample–the risk of selection bias was mini-
mised. Lastly, since our sample consisted of Swiss older patients, we do not know if our
findings are generalizable to other populations. However, as other countries reported similar
attitudes towards deprescribing (e.g. 88% willingness to deprescribe in Australia [1], 89% in
Italy [25] and 92% in the USA [27]) this increases the confidence in our findings.
To the best of our knowledge, we were the first to investigate the relation between medica-
tion appropriateness and patients’ willingness to deprescribe using validated tools. The Beers
criteria is the most widely used tool for medication appropriateness and has proven to be accu-
rate in the assessment of PIM [42,43]. The Beers 2019 version is updated according to the latest
evidence and includes drug-drug interactions when assessing PIMs. Lastly, we used the
rPATD questionnaire, which is validated and has been used internationally to assess willing-
ness to deprescribe [37,54]. We followed international standards with independent forward
and back translation to translate the rPATD into German.
Implications for future practice and research
Although we did not detect an association of PIM and willingness to deprescribe, we did see
positive trends of patients on PIM towards, for instance, the perception of having more side
effects (14%) and taking medication they no longer need (47%). However, since willingness to
deprescribe is equal, this implies that patients’ willingness does not seem to be driven by
knowledge that they are on a PIM. This again indicates the need to raise awareness about
PIMs in older patients with polypharmacy, especially in females. Clinicians should be encour-
aged to regularly discuss deprescribing and the fact that the risks and benefits of medication
use can change over time. Currently, patient education materials are increasingly being devel-
oped that will likely add to patients understanding of PIMs [55]. However, the group most
at risk for PIM are vulnerable (oldest-) old patients [13–15] that demonstrate highly varying
care wishes and needs, thereby challenging clinicians to provide appropriate care. Hence, in
addition to our main finding–medication appropriateness being independent of patients’
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willingness to have medication deprescribed–this pleads for an even bigger role of shared deci-
sion-making in the deprescribing process.
Future studies should further investigate the relationship between enabling factors of deprescrib-
ing and medication appropriateness and whether patients’ attitudes and beliefs about medications
may change with education [56]. Furthermore, they should focus on what patients consider inap-
propriate medication and which medications they would be willing to stop. Specific questions
about patients’ awareness about PIMs should be included in future research. As we found PIMs to
be more prevalent in females compared to males, gender specific causes of PIM should be assessed
in future studies. We also suggest focusing on specific classes and/or categories of medications in
future research into PIM and willingness to deprescribe as this has not yet been explored and could
be informative for translating into practice. Lastly, future studies should apply multiple PIM assess-
ment tools, as well as comprehensive medication reviews determining actual appropriateness.
Conclusion
We found PIM to be prevalent in the older population and patients to be generally willing to
deprescribe. Patients’ willingness to deprescribe was found to be irrespective of whether they
were taking one or more PIMs. Female gender and increasing number of prescribed medica-
tions were positively associated with PIM use. Our results imply that it is necessary to raise
awareness among older patients on PIMs, especially in females.
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